Apexigen, Inc. | Press Releases

Date	Title	View
August 4, 2022	Apexigen to Participate in the 2022 Wedbush PacGrow Healthcare Conference
August 1, 2022	Apexigen Completes Business Combination to Become a Publicly Listed Immuno-oncology Company
July 18, 2022	Apexigen and Brookline Capital Acquisition Corp. Announce Effectiveness of Registration Statement and Annual Stockholder Meeting to Approve the Proposed Business Combination
July 11, 2022	Apexigen to Participate in the Brookline Capital Markets Newport Symposium
June 29, 2022	Apexigen Announces Board Appointment and New Chair
June 8, 2022	Apexigen Appoints William Duke as Chief Financial Officer
June 6, 2022	Apexigen Announces Nature Medicine Publication and ASCO Presentation on the Phase 2 PRINCE Trial Showcasing Distinct Biosignatures in Metastatic Pancreatic Cancer Patients Treated with Sotigalimab and/or Nivolumab in Combination with Chemotherapy
May 9, 2022	Apexigen to Host Investor Day on Antibody Therapeutic Pipeline and Unique APXiMAB™ Platform
April 12, 2022	Apexigen Announces New Data from a Phase 2 Trial Evaluating its CD40 Antibody, Sotigalimab, in Combination with Pembrolizumab in Patients with Metastatic Melanoma Presented at the AACR Annual Meeting 2022
April 7, 2022	Apexigen Announces That New Data From Phase 2 Trial Evaluating its CD40 Antibody Sotigalimab in Combination With Pembrolizumab in Patients With Metastatic Melanoma Will Be Presented at the AACR Annual Meeting 2022